CD79B and non-Hodgkin lymphoma: Our study analyzed 13 studies (Phase I–III) and 1533 Non-Hodgkin Lymphoma (NHL) patients to evaluate the effectiveness of polatuzumab vedotin as a CD79B gene-targeting drug using a meta-analysis approach.